BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

795 related articles for article (PubMed ID: 31540133)

  • 1. Alcohol or Gut Microbiota: Who Is the Guilty?
    Meroni M; Longo M; Dongiovanni P
    Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31540133
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fecal microbiota manipulation prevents dysbiosis and alcohol-induced liver injury in mice.
    Ferrere G; Wrzosek L; Cailleux F; Turpin W; Puchois V; Spatz M; Ciocan D; Rainteau D; Humbert L; Hugot C; Gaudin F; Noordine ML; Robert V; Berrebi D; Thomas M; Naveau S; Perlemuter G; Cassard AM
    J Hepatol; 2017 Apr; 66(4):806-815. PubMed ID: 27890791
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alcoholic liver disease: the gut microbiome and liver cross talk.
    Hartmann P; Seebauer CT; Schnabl B
    Alcohol Clin Exp Res; 2015 May; 39(5):763-75. PubMed ID: 25872593
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Are Probiotics Effective in Targeting Alcoholic Liver Diseases?
    Hong M; Han DH; Hong J; Kim DJ; Suk KT
    Probiotics Antimicrob Proteins; 2019 Jun; 11(2):335-347. PubMed ID: 29687200
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intestinal permeability, microbial translocation, changes in duodenal and fecal microbiota, and their associations with alcoholic liver disease progression in humans.
    Maccioni L; Gao B; Leclercq S; Pirlot B; Horsmans Y; De Timary P; Leclercq I; Fouts D; Schnabl B; Stärkel P
    Gut Microbes; 2020 Nov; 12(1):1782157. PubMed ID: 32588725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gut Microbiota and Alcoholic Liver Disease.
    Scarpellini E; Forlino M; Lupo M; Rasetti C; Fava G; Abenavoli L; De Santis A
    Rev Recent Clin Trials; 2016; 11(3):213-9. PubMed ID: 27515958
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Links of gut microbiota composition with alcohol dependence syndrome and alcoholic liver disease.
    Dubinkina VB; Tyakht AV; Odintsova VY; Yarygin KS; Kovarsky BA; Pavlenko AV; Ischenko DS; Popenko AS; Alexeev DG; Taraskina AY; Nasyrova RF; Krupitsky EM; Shalikiani NV; Bakulin IG; Shcherbakov PL; Skorodumova LO; Larin AK; Kostryukova ES; Abdulkhakov RA; Abdulkhakov SR; Malanin SY; Ismagilova RK; Grigoryeva TV; Ilina EN; Govorun VM
    Microbiome; 2017 Oct; 5(1):141. PubMed ID: 29041989
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Gastrointestinal Microbiome: Alcohol Effects on the Composition of Intestinal Microbiota.
    Engen PA; Green SJ; Voigt RM; Forsyth CB; Keshavarzian A
    Alcohol Res; 2015; 37(2):223-36. PubMed ID: 26695747
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intestinal dysbiosis and permeability: the yin and yang in alcohol dependence and alcoholic liver disease.
    Stärkel P; Leclercq S; de Timary P; Schnabl B
    Clin Sci (Lond); 2018 Jan; 132(2):199-212. PubMed ID: 29352076
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alcohol, liver disease and the gut microbiota.
    Bajaj JS
    Nat Rev Gastroenterol Hepatol; 2019 Apr; 16(4):235-246. PubMed ID: 30643227
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gut-liver axis in alcoholic liver disease.
    Szabo G
    Gastroenterology; 2015 Jan; 148(1):30-6. PubMed ID: 25447847
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Microbiome as a therapeutic target in alcohol-related liver disease.
    Sarin SK; Pande A; Schnabl B
    J Hepatol; 2019 Feb; 70(2):260-272. PubMed ID: 30658727
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Microbiota-based treatments in alcoholic liver disease.
    Sung H; Kim SW; Hong M; Suk KT
    World J Gastroenterol; 2016 Aug; 22(29):6673-82. PubMed ID: 27547010
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting the gut microbiota to treat alcoholic liver diseases: evidence and promises.
    Leclercq S; de Timary P; Stärkel P
    Acta Gastroenterol Belg; 2020; 83(4):616-621. PubMed ID: 33321019
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The intestinal microbiota as a therapeutic target in the treatment of NAFLD and ALD.
    Huang W; Kong D
    Biomed Pharmacother; 2021 Mar; 135():111235. PubMed ID: 33561650
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The gut-liver axis in liver disease: Pathophysiological basis for therapy.
    Albillos A; de Gottardi A; Rescigno M
    J Hepatol; 2020 Mar; 72(3):558-577. PubMed ID: 31622696
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intestinal HIF-1α deletion exacerbates alcoholic liver disease by inducing intestinal dysbiosis and barrier dysfunction.
    Shao T; Zhao C; Li F; Gu Z; Liu L; Zhang L; Wang Y; He L; Liu Y; Liu Q; Chen Y; Donde H; Wang R; Jala VR; Barve S; Chen SY; Zhang X; Chen Y; McClain CJ; Feng W
    J Hepatol; 2018 Oct; 69(4):886-895. PubMed ID: 29803899
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lychee (Litchi chinensis Sonn.) Pulp Phenolic Extract Provides Protection against Alcoholic Liver Injury in Mice by Alleviating Intestinal Microbiota Dysbiosis, Intestinal Barrier Dysfunction, and Liver Inflammation.
    Xiao J; Zhang R; Zhou Q; Liu L; Huang F; Deng Y; Ma Y; Wei Z; Tang X; Zhang M
    J Agric Food Chem; 2017 Nov; 65(44):9675-9684. PubMed ID: 29041775
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modulation of the intestinal bile acid/farnesoid X receptor/fibroblast growth factor 15 axis improves alcoholic liver disease in mice.
    Hartmann P; Hochrath K; Horvath A; Chen P; Seebauer CT; Llorente C; Wang L; Alnouti Y; Fouts DE; Stärkel P; Loomba R; Coulter S; Liddle C; Yu RT; Ling L; Rossi SJ; DePaoli AM; Downes M; Evans RM; Brenner DA; Schnabl B
    Hepatology; 2018 Jun; 67(6):2150-2166. PubMed ID: 29159825
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alcoholic liver disease: focus on prodromal gut health.
    Park B; Lee HR; Lee YJ
    J Dig Dis; 2016 Aug; 17(8):493-500. PubMed ID: 27356233
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.